AstraZeneca’s Chief Executive, Pascal Soriot, expressed optimism about the interim data from a crucial lung cancer drug trial. The trial tested an experimental precision drug called datopotamab deruxtecan. While the results were released earlier, the company did not label them as “clinically meaningful,” which led to an 8% drop in the company’s shares.
Soriot addressed the issue during a media briefing after the release of better-than-expected quarterly results. He stated that the decision not to use the “clinically meaningful” description would become clear when the full results are disclosed, but he did not provide further details.
He emphasized that the overall data was very encouraging and described it as “statistically positive.” The company reaffirmed its commitment to proceed with filing the trial data with the U.S. Food and Drug Administration (FDA), which helped alleviate some investor concerns.
Susan Galbraith, the executive vice president of oncology R&D, reported that the FDA’s response to the data so far had been encouraging.
However, specific details about the timing of the final data release, the medical conference where it will be presented, or the timeline for seeking drug approval from the U.S. drug regulator were not disclosed by the executives during the briefing.